BioWorld: The Daily Biopharmaceutical News Source
WEBNeurological diseases index falls; Sarepta and Intra-Cellular report gains. As of the end of August 2024, the BioWorld Neurological Diseases Index (BNDI) reported a decline of 8.89%, lagging behind the Nasdaq Biotechnology Index, which gained 11.7%, and the Dow Jones Industrial Average, which rose by 7.05%. While a slight recovery from BNDI’s ...
Lerna Biopharma presents first-in-class GalNAc-siRNA ... - BioWorld
WEBNov 23, 2023 · Researchers from Lerna Biopharma Pte. Ltd. (formerly Cargene Therapeutics Pte. Ltd.) recently presented the discovery and preclinical evaluation of a first-in-class GalNAc-siRNA therapeutic, CG-LR1, being developed for …
License - BioWorld
WEBAug 20, 2024 · Triastek Inc., of Nanjing, China, scored a potential $1.2 billion collaboration and platform technology license deal with Biontech SE to manufacture oral RNA therapeutics with 3D printing technology. Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors.
| BioWorld
WEBFeb 19, 1997 · By Charles Craig. Ariad Pharmaceuticals Inc., with its technology for regulating gene expression, and Genovo Inc., with its expertise in gene delivery, formed a joint venture to develop therapies for controlled, long-term in vivo production of therapeutic proteins.. The two companies, expected to announce their alliance today, will focus on developing their gene therapies to compete in the $11 ...
New peptide antibiotics from the human microbiome | BioWorld
WEBAug 22, 2024 · The gastrointestinal tract could be key to developing new drugs to combat resistant bacteria. Computational analysis of the human microbiome has revealed a new class of peptides with antimicrobial potential that, once synthesized, inhibited the growth of several microorganisms in vitro and in vivo. “Antimicrobial resistance is one of the greatest threats to humanity, with more and more ...
Organoids making their US clinical debut with CIDP drug
WEBJul 15, 2022 · Organoids making their US clinical debut with CIDP drug. July 15, 2022. By Nuala Moran. The use of organoids in preclinical research has reached a tipping point, with U.S. FDA approval of the first drug to enter clinical trials on the basis of efficacy data derived only from these advanced cell models. BioWorld BioWorld MedTech Regulatory U.S.
China - BioWorld
WEB6 days ago · China biotechs rise to challenge Ozempic, Wegovy. Sep. 17, 2024. By Marian (YoonJee) Chu. No Comments. Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster therapies in China.
Today's news in brief | BioWorld
WEBBioWorld briefs for Sept. 17, 2024. BioWorld Briefs. Big pharma eyes China ‘at forefront of GLP-1 revolution’. Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and... Novo Nordisk seeks to repurpose GLP-1s, again, for the brain.
FDA report on NSE decisions: What does it not say?
WEBJun 17, 2011 · FDA's Center for Devices and Radiological Health published the results of its analysis of decisions on 510(k) applications between 2006 and 2010 (see the pdf of the report here), including some data from as far back as 2001, and several features jump out to the casual observer. The problem for CDRH managers is that the report suggest a number of stories – several of which the agency fails to ...
Cumulus raising $50M, spinning GPR68 small molecules into GIO
WEBAug 29, 2024 · Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up for clinical development, and spinning them into startups, gathers pace. At the same time, Nodus Oncology Ltd., the first spinout created around an acquired asset, has just reached in vivo proof of concept with its lead DNA damage ...